novo nordisk's wegovy reduces cardiovascular risk more than lilly's tirzepatide Weight-Loss Drug Lowers Major Heart Disease By 20%, Trial Says—Novo Nordisk Shares Surge Wegovy's heart benefits are not

This precision approach transforms nutrition guidance from generic advice into a personalized roadmap aligned with your unique genetic predispositions

The full deal structure, the lead asset, and what it means for AstraZeneca's obesity pipeline is broken down on www.lifesciencedaily.news #AstraZeneca #Obesity #GLP1 #WeightManagement #Pharma #DrugDevelopment #Biopharma #LifeSciences #CSPC #ChinaPharma #Licensing To view or add a comment, sign in The obesity-diabetes drug market has emerged as one of the pharmaceutical industry's most lucrative and competitive segments, with leading companies generating tens of billions in annual revenue

To view or add a comment, sign in Proposed theoretical mechanism of action: This infographic illustrates how antihypertensive peptides may help support cardiovascular and endothelial function by inhibiting ACE activity, lowering angiotensin II signaling, reducing vasoconstriction and aldosterone-related fluid retention, and improving vascular relaxation

If you fall into the category of someone who could actually benefit from them for diabetes or obesity treatment (or both!), they really can be lifesaving

Yes, both forms of semaglutide share similar side effects because they contain the same active ingredient

A novel alginate from Sargassum seaweed promotes diabetic wound healing by regulating oxidative stress and angiogenesis